Nanobiotix S.A. (NANO.PA)
EUR 3.48
(1.93%)
EUR 3.48
(1.93%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 41.66 Million EUR | -5.4% |
| 2022 | 44.04 Million EUR | 35.83% |
| 2021 | 32.42 Million EUR | -17.11% |
| 2020 | 39.11 Million EUR | 3.97% |
| 2019 | 37.62 Million EUR | 87.91% |
| 2018 | 20.02 Million EUR | 434.32% |
| 2017 | 3.74 Million EUR | -18.24% |
| 2016 | 4.58 Million EUR | 29.8% |
| 2015 | 3.53 Million EUR | 76.36% |
| 2014 | 2 Million EUR | 128.76% |
| 2013 | 875.17 Thousand EUR | -18.37% |
| 2012 | 1.07 Million EUR | 103.53% |
| 2011 | 526.76 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 40.72 Million EUR | 0.0% |
| 2023 FY | 41.66 Million EUR | -5.4% |
| 2023 Q4 | 41.66 Million EUR | 0.0% |
| 2023 Q2 | 39.92 Million EUR | 0.0% |
| 2022 Q2 | 31.14 Million EUR | 0.0% |
| 2022 FY | 44.04 Million EUR | 35.83% |
| 2022 Q4 | 44.04 Million EUR | 0.0% |
| 2021 Q2 | 39.13 Million EUR | 0.0% |
| 2021 FY | 32.42 Million EUR | -17.11% |
| 2021 Q4 | 32.42 Million EUR | 0.0% |
| 2020 Q2 | 44.06 Million EUR | 0.0% |
| 2020 FY | 39.11 Million EUR | 3.97% |
| 2020 Q4 | 39.11 Million EUR | 0.0% |
| 2019 Q2 | 35.89 Million EUR | 0.0% |
| 2019 FY | 37.62 Million EUR | 87.91% |
| 2019 Q4 | 37.62 Million EUR | 0.0% |
| 2018 FY | 20.02 Million EUR | 434.32% |
| 2018 Q2 | 3.79 Million EUR | 0.0% |
| 2018 Q4 | 20.02 Million EUR | 0.0% |
| 2017 FY | 3.74 Million EUR | -18.24% |
| 2017 Q4 | 3.74 Million EUR | 0.0% |
| 2017 Q2 | 4.07 Million EUR | 0.0% |
| 2016 Q2 | 3.01 Million EUR | 0.0% |
| 2016 FY | 4.58 Million EUR | 29.8% |
| 2016 Q4 | 4.58 Million EUR | 0.0% |
| 2015 FY | 3.53 Million EUR | 76.36% |
| 2015 Q4 | 3.53 Million EUR | 0.0% |
| 2015 Q2 | 3.51 Million EUR | 0.0% |
| 2014 Q4 | 2 Million EUR | 0.0% |
| 2014 Q2 | 1.1 Million EUR | 0.0% |
| 2014 FY | 2 Million EUR | 128.76% |
| 2013 Q4 | 875.17 Thousand EUR | 0.0% |
| 2013 Q2 | 929.08 Thousand EUR | 0.0% |
| 2013 FY | 875.17 Thousand EUR | -18.37% |
| 2012 FY | 1.07 Million EUR | 103.53% |
| 2012 Q4 | 1.07 Million EUR | 0.0% |
| 2011 FY | 526.76 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -3683.833% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 6.795% |
| Adocia SA | 4.54 Million EUR | -817.621% |
| Aelis Farma SA | 2.04 Million EUR | -1934.18% |
| Biophytis S.A. | 3.11 Million EUR | -1239.119% |
| Advicenne S.A. | 15.89 Million EUR | -162.079% |
| genOway Société anonyme | 5.51 Million EUR | -654.806% |
| IntegraGen SA | 642.28 Thousand EUR | -6386.268% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3371.667% |
| Neovacs S.A. | 650 Thousand EUR | -6309.231% |
| NFL Biosciences SA | 39.2 Thousand EUR | -106167.377% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -856.27% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -2025.153% |
| Sensorion SA | 1.24 Million EUR | -3257.211% |
| Theranexus Société Anonyme | 2.46 Million EUR | -1593.002% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -968.753% |
| TheraVet SA | 1 Million EUR | -4063.506% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -503.244% |
| argenx SE | 15.35 Million EUR | -171.33% |
| BioSenic S.A. | 15.57 Million EUR | -167.514% |
| Celyad Oncology SA | 902 Thousand EUR | -4518.625% |
| DBV Technologies S.A. | 4.52 Million USD | -820.46% |
| Galapagos NV | 4.94 Million EUR | -742.638% |
| Genfit S.A. | 62.25 Million EUR | 33.08% |
| GeNeuro SA | 6.49 Million EUR | -541.683% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -12010.465% |
| Innate Pharma S.A. | 30.6 Million EUR | -36.113% |
| Inventiva S.A. | 25.61 Million EUR | -62.633% |
| MaaT Pharma SA | 5.42 Million EUR | -667.926% |
| MedinCell S.A. | 52.8 Million EUR | 21.098% |
| Onward Medical N.V. | 16.3 Million EUR | -155.489% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -1107.321% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -17.326% |
| Oxurion NV | 117 Thousand EUR | -35506.838% |
| Pharming Group N.V. | 123.65 Million EUR | 66.31% |
| Poxel S.A. | 40.14 Million EUR | -3.779% |
| GenSight Biologics S.A. | 1.04 Million EUR | -3875.191% |
| Transgene SA | 17 Thousand EUR | -244958.824% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 98.552% |
| Valneva SE | 132.76 Million EUR | 68.622% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |